Physician profile
Mamoon Daas
NPI 1053318576
$5,181.11
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $934 · 2020: $809 · 2021: $1,503 · 2022: $1,870 · 2024: $65.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $65.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $65.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $809.71 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $737.93 | 2019-2022 | |
| Novo Nordisk INC | $503.86 | 2021-2022 | |
| Abbvie INC. | $483.55 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $402.47 | 2019-2022 | |
| Lilly USA, LLC | $370.64 | 2019-2022 | |
| Glaxosmithkline, LLC. | $219.64 | 2020-2024 | Trelegy Ellipta |
| Amgen INC. | $198.69 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.32 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $185.97 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $161.78 | 2021-2022 | |
| Abbott Laboratories | $129.86 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $129.80 | 2022 | |
| Novartis Pharmaceuticals Corporation | $119.00 | 2019-2022 | |
| Allergan, INC. | $79.66 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.65 | 2020-2022 | |
| Pfizer INC. | $60.48 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $51.77 | 2021 | |
| Sanofi Pasteur INC. | $44.56 | 2022 | |
| Ucb, INC. | $43.01 | 2024 | Nayzilam |
| Dexcom, INC. | $23.38 | 2021 | |
| Astellas Pharma US INC | $21.38 | 2021 | |
| Exeltis, USA INC. | $21.30 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.78 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.69 | 2022 | |
| Seqirus USA INC | $18.06 | 2020 | |
| Eisai INC. | $16.53 | 2021 | |
| Ironshore Pharmaceuticals INC. | $15.84 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.12 | 2020 | |
| Neurocrine Biosciences, INC. | $13.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mamoon Daas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.